Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center.

ScientificWorldJournal · 2014 · PMC4127276 · PMID 25136668

Europe PMC DOI

hedged sentence

0.0340

closest p · 0.7× alpha

0.0340

boldest claim

The sentences

a significant trendP = 0.034actually significant

Also, there was a significant trend towards less advanced nodal disease in the neoadjuvant group than in the adjuvant group ( P = 0.034) ( Table 3 ). 3.5.

also in 6,248 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.